Market Cap 20.14B
Revenue (ttm) 29.05M
Net Income (ttm) -171.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -592.01%
Debt to Equity Ratio 0.00
Volume 5,616,200
Avg Vol 5,555,846
Day's Range N/A - N/A
Shares Out 715.70M
Stochastic %K 11%
Beta 1.20
Analysts Strong Sell
Price Target $35.67

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7400 3347
Website: roivant.com
Address:
50 Broadway, 7th Floor, London, United Kingdom
dick_dasterdly
dick_dasterdly Apr. 21 at 10:29 PM
$ROIV Bought this @ $11.13 back on July 18th , 2024. Slowly but surely here folks. Loonnggg play for me. Rich pipeline. And consolidating each and every day..
0 · Reply
NettyLite
NettyLite Apr. 21 at 7:28 PM
$ROIV I thought about also buying Abus but with the slightest bit of research I realized that would be dumb. Abus is roiv's bitch. Y'all didn't do your research now go home and get your shine box
0 · Reply
mj6534
mj6534 Apr. 20 at 10:16 PM
$ABUS $ROIV Androski doing absolutely nothing for us. 🤡
0 · Reply
Thepatientone
Thepatientone Apr. 20 at 7:20 PM
$ABUS - I truly did not understand this rationale. If there was going to be an appeal for the larger amount of the agreement why not proceed to trial... You hold the position that there is an infringement and was willing full for 5 years and you make this decision. I think this new management team came with only one purpose to bring cash to the $ROIV coffins sooner than later. I wonder if we have the right to transparency regarding the logic this management had and not one penny in additional stocks.
3 · Reply
CapitalismUSA
CapitalismUSA Apr. 17 at 11:47 AM
$ABUS $ROIV Agree…voted against the compensation/additional share proposal. Also voted against Androski. We need an independent CEO, not a ROIV puppet
2 · Reply
buffalosoldiertwo
buffalosoldiertwo Apr. 17 at 10:20 AM
$ABUS Why do we need 16MM new shares for executive compensation? It’s obvious they’re winding down the company. Sofia exits before phase 2’s complete, $ROIV takes over the board, company publicly states return litigation process to shareholders signaling no intention of pursuing phase 3 for AB-736, down to 19 employees. We’re obviously in a multi year process of monetizing the assets. This unwinding process is managed by consultants (Morgan Stanley, Goldman Sacks, etc), not anything that $ROIV’s puppet CEO brings to the table. I’m a hard no on item 2. We cannot enrich a C Suite that is adding no value to shareholders. The value was added when the decision was made to monetize all the assets. Done, gone, history. With JP Morgan at your back a monkey could manage the process from here on out. There’s only 19 total employees ($4 MILLION PER EMPLOYEE). For gods sake. No, no, no.
4 · Reply
dick_dasterdly
dick_dasterdly Apr. 17 at 8:57 AM
$ROIV I trust the pipeline. Period.
0 · Reply
sheepmanct
sheepmanct Apr. 15 at 12:27 PM
$ROIV ABUS news if interested- https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-receives-us-fda-fast-track-designation-imdusiran
0 · Reply
Nile1
Nile1 Apr. 14 at 6:37 PM
$ABUS $ABUS so white fort is only halfway from taking over $ROIV , nice 😀
1 · Reply
BreakoutsHappen
BreakoutsHappen Apr. 14 at 10:03 AM
Vix under 19, 50% stocks above ma40. Seems a good day for breakouts. $TIGO $KNSA $ROIV
0 · Reply
Latest News on ROIV
Roivant Sciences Transcript: Study result

Apr 2, 2026, 8:00 AM EDT - 23 days ago

Roivant Sciences Transcript: Study result


Roivant Sciences Transcript: Status update

Mar 3, 2026, 4:45 PM EST - 7 weeks ago

Roivant Sciences Transcript: Status update


Roivant Sciences Earnings Call Transcript: Q3 2026

Feb 6, 2026, 8:00 AM EST - 2 months ago

Roivant Sciences Earnings Call Transcript: Q3 2026


Roivant Sciences Transcript: Investor Day 2025

Dec 11, 2025, 8:00 AM EST - 4 months ago

Roivant Sciences Transcript: Investor Day 2025


Roivant Sciences Earnings Call Transcript: Q2 2026

Nov 10, 2025, 8:00 AM EST - 5 months ago

Roivant Sciences Earnings Call Transcript: Q2 2026


Roivant Sciences Transcript: Study Result

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Roivant Sciences Transcript: Study Result


Roivant Sciences Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 8 months ago

Roivant Sciences Transcript: Study Update


Roivant Sciences Earnings Call Transcript: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Roivant Sciences Earnings Call Transcript: Q1 2026


Roivant Sciences Transcript: Status Update

Jun 17, 2025, 1:00 PM EDT - 11 months ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Earnings Call Transcript: Q4 2025

May 29, 2025, 8:00 AM EDT - 11 months ago

Roivant Sciences Earnings Call Transcript: Q4 2025


Roivant Sciences Transcript: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Earnings Call Transcript: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q3 2025


Roivant's lung disease drug fails mid-stage trial

Dec 3, 2024, 7:19 AM EST - 1 year ago

Roivant's lung disease drug fails mid-stage trial


Roivant Sciences Earnings Call Transcript: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q2 2025


Roivant Flips a Skin Drug to Organon

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN


Roivant Sciences Transcript: Study Update

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Study Update


Roivant Sciences Earnings Call Transcript: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q1 2025


Roivant Sciences Earnings Call Transcript: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings Call Transcript: Q4 2024


Roivant Sciences Transcript: Status Update

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Transcript: Status Update


Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:28 AM EDT - 2 years ago

Roivant's anti-inflammatory drug succeeds in mid-stage study


Roivant Sciences Earnings Call Transcript: Q3 2024

Feb 13, 2024, 8:00 AM EST - 2 years ago

Roivant Sciences Earnings Call Transcript: Q3 2024


Roivant Sciences Earnings Call Transcript: Q2 2024

Nov 13, 2023, 8:00 AM EST - 2 years ago

Roivant Sciences Earnings Call Transcript: Q2 2024


Roivant Sciences Transcript: Investor Update

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Roivant Sciences Transcript: Investor Update


Roivant Sciences Earnings Call Transcript: Q1 2024

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings Call Transcript: Q1 2024


Roivant Sciences Earnings Call Transcript: Q4 2023

Jun 28, 2023, 8:00 AM EDT - 3 years ago

Roivant Sciences Earnings Call Transcript: Q4 2023


Roivant Sciences Transcript: Investor Update

Jun 22, 2023, 8:00 AM EDT - 3 years ago

Roivant Sciences Transcript: Investor Update


Roivant Sciences Transcript: Study Result

Mar 15, 2023, 6:00 AM EDT - 3 years ago

Roivant Sciences Transcript: Study Result


Roivant Sciences Earnings Call Transcript: Q3 2023

Feb 13, 2023, 7:00 AM EST - 3 years ago

Roivant Sciences Earnings Call Transcript: Q3 2023


Roivant Sciences Transcript: Study Result

Jan 4, 2023, 7:00 AM EST - 3 years ago

Roivant Sciences Transcript: Study Result


Roivant Sciences Earnings Call Transcript: Q2 2023

Nov 14, 2022, 7:00 AM EST - 3 years ago

Roivant Sciences Earnings Call Transcript: Q2 2023


Roivant Sciences Transcript: Investor Day 2022

Sep 28, 2022, 11:00 AM EDT - 3 years ago

Roivant Sciences Transcript: Investor Day 2022


Roivant Sciences Earnings Call Transcript: Q1 2023

Aug 15, 2022, 8:00 AM EDT - 4 years ago

Roivant Sciences Earnings Call Transcript: Q1 2023


Roivant Sciences Earnings Call Transcript: Q4 2022

Jun 28, 2022, 8:00 AM EDT - 4 years ago

Roivant Sciences Earnings Call Transcript: Q4 2022


Roivant Sciences Transcript: Investor Update

May 24, 2022, 8:00 AM EDT - 4 years ago

Roivant Sciences Transcript: Investor Update


Roivant Sciences Transcript: Status Update

Feb 28, 2022, 7:00 AM EST - 4 years ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Earnings Call Transcript: Q3 2022

Feb 14, 2022, 7:00 AM EST - 4 years ago

Roivant Sciences Earnings Call Transcript: Q3 2022


dick_dasterdly
dick_dasterdly Apr. 21 at 10:29 PM
$ROIV Bought this @ $11.13 back on July 18th , 2024. Slowly but surely here folks. Loonnggg play for me. Rich pipeline. And consolidating each and every day..
0 · Reply
NettyLite
NettyLite Apr. 21 at 7:28 PM
$ROIV I thought about also buying Abus but with the slightest bit of research I realized that would be dumb. Abus is roiv's bitch. Y'all didn't do your research now go home and get your shine box
0 · Reply
mj6534
mj6534 Apr. 20 at 10:16 PM
$ABUS $ROIV Androski doing absolutely nothing for us. 🤡
0 · Reply
Thepatientone
Thepatientone Apr. 20 at 7:20 PM
$ABUS - I truly did not understand this rationale. If there was going to be an appeal for the larger amount of the agreement why not proceed to trial... You hold the position that there is an infringement and was willing full for 5 years and you make this decision. I think this new management team came with only one purpose to bring cash to the $ROIV coffins sooner than later. I wonder if we have the right to transparency regarding the logic this management had and not one penny in additional stocks.
3 · Reply
CapitalismUSA
CapitalismUSA Apr. 17 at 11:47 AM
$ABUS $ROIV Agree…voted against the compensation/additional share proposal. Also voted against Androski. We need an independent CEO, not a ROIV puppet
2 · Reply
buffalosoldiertwo
buffalosoldiertwo Apr. 17 at 10:20 AM
$ABUS Why do we need 16MM new shares for executive compensation? It’s obvious they’re winding down the company. Sofia exits before phase 2’s complete, $ROIV takes over the board, company publicly states return litigation process to shareholders signaling no intention of pursuing phase 3 for AB-736, down to 19 employees. We’re obviously in a multi year process of monetizing the assets. This unwinding process is managed by consultants (Morgan Stanley, Goldman Sacks, etc), not anything that $ROIV’s puppet CEO brings to the table. I’m a hard no on item 2. We cannot enrich a C Suite that is adding no value to shareholders. The value was added when the decision was made to monetize all the assets. Done, gone, history. With JP Morgan at your back a monkey could manage the process from here on out. There’s only 19 total employees ($4 MILLION PER EMPLOYEE). For gods sake. No, no, no.
4 · Reply
dick_dasterdly
dick_dasterdly Apr. 17 at 8:57 AM
$ROIV I trust the pipeline. Period.
0 · Reply
sheepmanct
sheepmanct Apr. 15 at 12:27 PM
$ROIV ABUS news if interested- https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-receives-us-fda-fast-track-designation-imdusiran
0 · Reply
Nile1
Nile1 Apr. 14 at 6:37 PM
$ABUS $ABUS so white fort is only halfway from taking over $ROIV , nice 😀
1 · Reply
BreakoutsHappen
BreakoutsHappen Apr. 14 at 10:03 AM
Vix under 19, 50% stocks above ma40. Seems a good day for breakouts. $TIGO $KNSA $ROIV
0 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 13 at 9:38 PM
$ROIV: a hot biotech found with a @MarketSurge scanner. Power gap on Phase III trial data...and only up more from there. 30+ and it'll soar. We're long from the recent dip in the Live Trading Room. #IBDPartner @MarketSurge @InvestorsBusinessDaily
1 · Reply
JFDI
JFDI Apr. 13 at 2:04 PM
$ROIV wow
0 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 9 at 7:34 PM
$ROIV rallied 20% on an update on their pipeline, with progress better than expected. The power gap is holding and now the stock is printing a rounded bottom bonce off the pullback to the rising 50sma. #IBDPartner @MarketSurge @InvestorsBusinessDaily
1 · Reply
bbbloo
bbbloo Apr. 9 at 12:55 PM
$ROIV anybody know why this looks like it is popping a little? ty!
0 · Reply
DocPharm
DocPharm Apr. 7 at 3:17 PM
$ABUS $PFE $BNTX $ROIV limits set for dip Along with other non-bio/pharm names
0 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 6 at 3:08 PM
$XBI: we haven't done much with bios lately (beyond $ROIV shares in the Live Trading Room) but this bullish rectangle looks to be ready to break to upside. 142 is the PT.
0 · Reply
Beach27
Beach27 Apr. 3 at 1:55 PM
$ROIV Gemini said Vanguard change the way they look at total shares from being all under Vanguard to being in all the funds that hold ROIV. Did they really sell?
0 · Reply
DocPharm
DocPharm Apr. 2 at 8:40 PM
$ABUS $ROIV So Whitefort and Vanguard sold all of their ROIV shares Vivek sold about 1/2 of his, along with some other large firms and other execs… Intriguing to say the least
8 · Reply
sheepmanct
sheepmanct Apr. 2 at 9:18 AM
$ROIV Some early morning news releases https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab https://investor.roivant.com/news-releases/news-release-details/priovant-expands-brepocitinib-development-program-new-phase-2b3 https://investor.roivant.com/news-releases/news-release-details/roivant-announces-expansion-brepocitinib-development-program-new
0 · Reply
AlertsAndNews
AlertsAndNews Mar. 29 at 9:35 PM
$ROIV New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis what a chart here lately too. "Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reduction"
0 · Reply
sheepmanct
sheepmanct Mar. 28 at 9:07 PM
$ROIV NEJM article https://investor.roivant.com/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-phase-3-valor/
0 · Reply
MikiTrader
MikiTrader Mar. 25 at 10:24 PM
$ROIV No wonder it went up.
1 · Reply